Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Michele Pavarana"'
Autor:
Michele Rota, Federico Sganzerla, Michele Zuffante, Andrea Mafficini, Michele Pavarana, Michele Milella
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
Gastrointestinal stromal tumors (GISTs) are the most frequent mesenchymal tumors of the gastrointestinal tract, usually arising in the stomach or in the small bowel. Most GISTs are diagnosed early due to the presence of symptoms (e.g., abdominal disc
Externí odkaz:
https://doaj.org/article/b108cd57014f46898c0cd2d745f4ac65
Autor:
Nicola Simoni, Gabriella Rossi, Giulio Benetti, Michele Zuffante, Renato Micera, Michele Pavarana, Stefania Guariglia, Emanuele Zivelonghi, Valentina Mengardo, Jacopo Weindelmayer, Simone Giacopuzzi, Giovanni de Manzoni, Carlo Cavedon, Renzo Mazzarotto
Publikováno v:
Frontiers in Oncology, Vol 10 (2020)
Background and ObjectiveThe aim of this study was to assess the ability of Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography (18F-FDG PET/CT) to provide functional information useful in predicting pathological response to an intensi
Externí odkaz:
https://doaj.org/article/0a4360dfbed441928644bc5bb3d32ea6
Autor:
Valeria Merz, Camilla Zecchetto, Francesca Simionato, Alessandro Cavaliere, Simona Casalino, Michele Pavarana, Simone Giacopuzzi, Maria Bencivenga, Anna Tomezzoli, Raffaela Santoro, Vita Fedele, Serena Contarelli, Irene Rossi, Serena Giacomazzi, Martina Pasquato, Cristiana Piazzola, Stefano Milleri, Giovanni de Manzoni, Davide Melisi
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 12 (2020)
Background: Prognosis of patients affected by metastatic esophageal–gastric junction (EGJ) or gastric cancer (GC) remains dismal. Trastuzumab, an anti-HER2 monoclonal antibody, is the only targeted agent approved for the first-line treatment of pat
Externí odkaz:
https://doaj.org/article/4b431a90dd5e4990a7ff617f4d3684eb
Autor:
Joris van de Haar, Xuhui Ma, Salo N. Ooft, Pim W. van der Helm, Louisa R. Hoes, Sara Mainardi, David J. Pinato, Kristi Sun, Lisa Salvatore, Giampaolo Tortora, Ina Valeria Zurlo, Silvana Leo, Riccardo Giampieri, Rossana Berardi, Fabio Gelsomino, Valeria Merz, Federica Mazzuca, Lorenzo Antonuzzo, Gerardo Rosati, Chara Stavraka, Paul Ross, Maria Grazia Rodriquenz, Michele Pavarana, Carlo Messina, Timothy Iveson, Federica Zoratto, Anne Thomas, Elisabetta Fenocchio, Margherita Ratti, Ilaria Depetris, Massimiliano Cergnul, Cristina Morelli, Michela Libertini, Alessandro Parisi, Michele De Tursi, Nicoletta Zanaletti, Ornella Garrone, Janet Graham, Raffaella Longarini, Stefania Maria Gobba, Angelica Petrillo, Emiliano Tamburini, Nicla La Verde, Fausto Petrelli, Vincenzo Ricci, Lodewyk F. A. Wessels, Michele Ghidini, Alessio Cortellini, Emile E. Voest, Nicola Valeri
Publikováno v:
Nature Medicine
Genomics has greatly improved how patients with cancer are being treated; however, clinical-grade genomic biomarkers for chemotherapies are currently lacking. Using whole-genome analysis of 37 patients with metastatic colorectal cancer (mCRC) treated
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5fb49b9ab0cd07171cb1da7854395935
https://doi.org/10.1038/s41591-023-02240-8
https://doi.org/10.1038/s41591-023-02240-8
Autor:
Simone Giacopuzzi, Lorena Torroni, Maria Bencivenga, Jacopo Weindelmayer, Maria Clelia Gervasi, Giuseppe Verlato, Michele Pavarana, Gabriella Rossi, Giovanni de Manzoni
Introduction. RCTs support neoadjuvant chemoradiotherapy (nCRT) followed by surgery in Locally Advanced Esophago-Gastric Junction (LA-EGJ) adenocarcinoma. However, RCTs are performed in highly controlled settings with limited representativeness of re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::54b705db109d85867cad5a47b90347f1
https://hdl.handle.net/11562/1093287
https://hdl.handle.net/11562/1093287
Autor:
Francesco Casella, Maria Bencivenga, Riccardo Rosati, Uberto Romario Fumagalli, Daniele Marrelli, Fabio Pacelli, Antonio Macrì, Annibale Donini, Lorena Torroni, Michele Pavarana, Giovanni De Manzoni
Objectives Peritoneal carcinomatosis is the most frequent site of metastases in patients with gastric cancer. Current standard treatment is palliative systemic chemotherapy with very poor prognosis. Cytoreductive surgery (CRS) combined with hyperther
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5641c8f61ae36758455f696a5aae6140
Publikováno v:
Gastric Cancer: the 25-year R-Evolution ISBN: 9783030731571
Over the years the treatment strategy of gastric cancer (GC) has been modified to improve clinical outcome. Neoadjuvant and perioperative therapies are emerging as the new standard of care in the setting of locally advanced disease, with systemic tre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2e795680b295bf283f962352a2ce8fee
https://doi.org/10.1007/978-3-030-73158-8_11
https://doi.org/10.1007/978-3-030-73158-8_11
Autor:
Teodoro Sava, Michele Pavarana
Publikováno v:
Updates in Surgery ISBN: 9788847023291
There are few studies of the treatment of relapse in patients with esophageal squamous cell cancer (ESCC). Moreover, those trials were not randomized and without convincing data. Cumulative overall 1-year and 2-year survival rates after recurrence we
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::059f8938c3e1e7eca532346e7cee2cfe
https://doi.org/10.1007/978-88-470-2330-7_17
https://doi.org/10.1007/978-88-470-2330-7_17
Autor:
Michele Pavarana, Teodoro Sava
Publikováno v:
Updates in Surgery ISBN: 9788847023291
There is considerable debate in the literature on the appropriate preoperative treatment of esophageal squamous cell carcinoma (ESCC), with valid options being chemotherapy (CT), chemoradiotherapy (CRT), followed or not by surgery. Some authors are o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::695c3dbc1e7902cea74acce521d3d5d9
https://doi.org/10.1007/978-88-470-2330-7_15
https://doi.org/10.1007/978-88-470-2330-7_15